Xu Fangdan, Xu Ying, Qiu Jianping
The Affiliated Suzhou Hospital of Nanjing Medical University, Department of Obstetrics and Gynecology, Suzhou, Jiangsu Province, China.
J Med Biochem. 2025 Jul 4;44(4):770-775. doi: 10.5937/jomb0-56632.
To evaluate the therapeutic effects of Tripterygium wilfordii glycosides on endometriosis (EMs) and their effects on serum sex hormone levels, tumour markers, and inflammatory factors (serum CA125, CA199, Estradiol, FSH, IL-6, TNF-a).
A total of 108 patients were randomly divided into control, progesterone, and Tripterygium wilfordii glycoside-treated groups, each receiving treatment for three months. The clinical efficacy and serum levels of estradiol, follicle-stimulating hormone, tumour markers (cancer antigen125 and cancer antigen199), and pro-inflammatory cytokines were compared before and after treatment.
The Tripterygium wilfordii glycoside group exhibited a significantly higher clinically effective rate (90.74% versus 75.93%) and more significant reductions in estradiol, follicle-stimulating hormone, cancer antigen125, cancer antigen199, IL-6, TNF-a, and HSCRP levels than the control group.
Tripterygium glycosides exhibit significant clinical efficacy in treating patients with EMS by significantly improving serum sex hormone levels, reducing tumour marker levels, alleviating inflammatory reactions, and exerting minimal toxic side effects.
评估雷公藤多苷对子宫内膜异位症（EMs）的治疗效果及其对血清性激素水平、肿瘤标志物和炎症因子（血清CA125、CA199、雌二醇、促卵泡生成素、白细胞介素-6、肿瘤坏死因子-α）的影响。
将108例患者随机分为对照组、孕酮组和雷公藤多苷治疗组，每组接受治疗3个月。比较治疗前后的临床疗效以及雌二醇、促卵泡生成素、肿瘤标志物（癌抗原125和癌抗原199）和促炎细胞因子的血清水平。
雷公藤多苷组的临床有效率显著更高（90.74%对75.93%），与对照组相比，雌二醇、促卵泡生成素、癌抗原125、癌抗原199、白细胞介素-6、肿瘤坏死因子-α和超敏C反应蛋白水平的降低更显著。
雷公藤多苷通过显著改善血清性激素水平、降低肿瘤标志物水平、减轻炎症反应并产生最小的毒副作用，在治疗子宫内膜异位症患者方面显示出显著的临床疗效。
